
ALT A table showing the clinical end points at 1 year (intention-to-treat analysis). It compares two groups: Ticagrelor-Policy Group (9444 patients) and Prasugrel-Policy Group (7651 patients). Primary end point shows 1113 events in the Ticagrelor-Policy Group and 848 in the Prasugrel-Policy Group. Secondary end points are listed, including death from any cause, myocardial infarction, stroke, major bleeding, and stent thrombosis, with corresponding patient numbers and percentages for each group. Odds ratios with confidence intervals are provided.

ALT A line graph shows the percent change in triglyceride levels over 24 weeks. There are four lines: placebo (grey), MAR001 300 mg (purple), MAR001 450 mg (light blue), and MAR001 900 mg (dark blue), each starting at zero. Standard error bars are included. Below, a table lists the number of participants for each group at various time points.














